Pacira BioSciences Reports First Quarter 2020 Financial Results and Business Update
-- Total revenues increased 16 percent over prior year first quarter --
-- Conference call today at
“Prior to headwinds from the COVID-19 pandemic, which began in mid-March, we saw growing demand for EXPAREL continue with year-over-year growth rates of over 20 percent in January and February. Specifically, we saw demand continue to expand within the anesthesia community with EXPAREL-based nerve and field blocks continuing to take hold as institutional protocol for a variety of surgical procedures,” said
First Quarter 2020 Financial Results
- Total revenues were
$105.7 million in the first quarter of 2020, a 16% increase over the$91.3 million reported for the first quarter of 2019.
- EXPAREL net product sales were
$101.3 million in the first quarter of 2020, a 12% increase over the$90.6 million reported for the first quarter of 2019.
- First quarter iovera° net product sales were
$2.3 million . Pacira began recognizing sales of iovera° inApril 2019 after completing its acquisition ofMyoScience, Inc. , a privately held medical technology company.
- Sales of bupivacaine liposome injectable suspension to a third-party licensee for use in veterinary practice were
$1.2 million in the first quarter of 2020, compared to$0.3 million in 2019.
- First quarter royalty revenue was
$0.9 million compared to$0.4 million in 2019.
- Total operating expenses were
$88.6 million in the first quarter of 2020, compared to$90.2 million in the first quarter of 2019.
- Research and development (R&D) expenses were
$15.8 million in the first quarter of 2020, compared to$14.4 million in the first quarter of 2019. R&D expenses include$6.6 million and$6.4 million of product development and manufacturing capacity expansion costs in the first quarters of 2020 and 2019, respectively.
- Selling, general and administrative (SG&A) expenses were
$44.8 million in the first quarter of 2020, compared to$47.3 million in the first quarter of 2019.
- GAAP net income was
$8.2 million , or$0.19 per share (basic and diluted) in the first quarter of 2020, compared to a GAAP net loss of$2.8 million , or$0.07 per share (basic and diluted), in the first quarter of 2019.
- Non-GAAP net income was
$22.8 million , or$0.54 per share (basic) and$0.53 per share (diluted), in the first quarter of 2020, compared to non-GAAP net income of$9.3 million , or$0.22 per share (basic and diluted), in the first quarter of 2019.
- Pacira ended the first quarter of 2020 with cash, cash equivalents, short-term and long-term investments (“cash”) of
$353.6 million . Cash provided by operations was$6.2 million in the first quarter of 2020, compared to$3.5 million in the first quarter of 2019.
- Pacira had 42.0 million basic weighted average shares of common stock outstanding in the first quarter of 2020.
- Pacira had 42.8 million diluted weighted average shares of common stock outstanding in the first quarter of 2020.
See “Non-GAAP Financial Information” below.
2020 Financial Guidance
Prior to
Today’s Conference Call and Webcast Reminder
The Pacira management team will host a conference call to discuss the company’s financial results and recent developments today,
For those unable to participate in the live call, a replay will be available at 1-855-859-2056 (domestic) or 1-404-537-3406 (international) using the passcode 8568879. The replay of the call will be available for one week from the date of the live call. The webcast will be available on the Pacira website for approximately two weeks following the call.
Non-GAAP Financial Information
This press release contains financial measures that do not comply with
These measures supplement Pacira’s financial results prepared in accordance with GAAP. Pacira management uses these measures to better analyze its financial results, estimate its future cost of goods sold, gross margins, R&D expense and SG&A expense outlook for 2020 and to help make managerial decisions. In management’s opinion, these non-GAAP measures are useful to investors and other users of our financial statements by providing greater transparency into the operating performance at Pacira and its future outlook. Such measures should not be deemed to be an alternative to GAAP requirements or a measure of liquidity for Pacira. Non-GAAP measures are also unlikely to be comparable with non-GAAP disclosures released by other companies. See the tables below for a reconciliation of GAAP to non-GAAP measures.
About
About EXPAREL
EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.
Important Safety Information for Patients
EXPAREL should not be used in obstetrical paracervical block anesthesia. In studies where EXPAREL was injected into the wound, the most common side effects were nausea, constipation, and vomiting. In studies where EXPAREL was injected near a nerve, the most common side effects were nausea, fever, and constipation. EXPAREL is not recommended to be used in patients younger than 18 years old or in pregnant women. Tell your healthcare provider if you have liver disease, since this may affect how the active ingredient (bupivacaine) in EXPAREL is eliminated from your body. EXPAREL should not be injected into the spine, joints, or veins. The active ingredient in EXPAREL: can affect your nervous system and your cardiovascular system; may cause an allergic reaction; may cause damage if injected into your joints.
About iovera°
The iovera° system is used to destroy tissue during surgical procedures by applying freezing cold. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. It is also indicated for the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days. In one study, the majority of the patients suffering from osteoarthritis of the knee experienced pain and system relief beyond 150 days.1 The iovera° system’s “1×90” Smart Tip configuration (indicating one needle which is 90 mm long) can also facilitate target nerve location by conducting electrical nerve stimulation from a separate nerve stimulator. The iovera° system is not indicated for treatment of central nervous system tissue.
1Radnovich, R. et al. “Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial.” Osteoarthritis and Cartilage (2017) p1-10.
Important Safety Information
The iovera° system is contraindicated for use in patients with the following: Cryoglobulinemia; Paroxysmal cold hemoglobinuria; cold urticaria; Raynaud’s disease; open and/or infected wounds at or near the treatment line. Potential complications: As with any surgical treatment that uses needle-based therapy, there is potential for temporary site-specific reactions, including but not limited to: bruising (ecchymosis); swelling (edema); inflammation and/or redness (erythema); pain and/or tenderness; altered sensation (localized dysesthesia). Typically, these reactions resolve with no physician intervention. Patients may help the healing process by applying ice packs to the affected sites, and by taking over-the-counter analgesics.
Forward-Looking Statements
Any statements in this press release about the company’s future expectations, plans, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the impact of the worldwide COVID-19 (Coronavirus) epidemic and related global economic conditions on our business and results of operations; the success of the company’s sales and manufacturing efforts in support of the commercialization of EXPAREL; the rate and degree of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and the company’s ability to serve those markets; the company’s plans to expand the use of EXPAREL to additional indications and opportunities, and the timing and success of any related clinical trials; the ability to realize anticipated benefits and synergies from the acquisition of
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
2020 |
2019 |
||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash, cash equivalents and short-term investments | $ | 318,464 | $ | 291,950 | |||
| Accounts receivable, net | 38,988 | 47,530 | |||||
| Inventories, net | 59,666 | 58,296 | |||||
| Prepaid expenses and other current assets | 14,476 | 10,781 | |||||
| Total current assets | 431,594 | 408,557 | |||||
| Long-term investments | 35,120 | 64,798 | |||||
| Fixed assets, net | 108,105 | 104,681 | |||||
| Right-of-use assets, net | 37,613 | 38,124 | |||||
| 99,547 | 99,547 | ||||||
| Intangible assets, net | 102,421 | 104,387 | |||||
| Equity investment and other assets | 6,979 | 10,971 | |||||
| Total assets | $ | 821,379 | $ | 831,065 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 15,850 | $ | 12,799 | |||
| Accrued expenses | 44,717 | 70,427 | |||||
| Lease liabilities | 3,968 | 4,935 | |||||
| Contingent consideration | 14,041 | 18,179 | |||||
| Income taxes payable | 1,737 | 1,333 | |||||
| Total current liabilities | 80,313 | 107,673 | |||||
| Convertible senior notes | 310,078 | 306,045 | |||||
| Lease liabilities | 40,189 | 40,938 | |||||
| Contingent consideration | 15,227 | 19,963 | |||||
| Other liabilities | 1,535 | 1,502 | |||||
| Total stockholders’ equity | 374,037 | 354,944 | |||||
| Total liabilities and stockholders’ equity | $ | 821,379 | $ | 831,065 | |||
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
(unaudited)
| Three Months Ended | |||||||
| 2020 | 2019 | ||||||
| Net product sales: | |||||||
| EXPAREL | $ | 101,269 | $ | 90,615 | |||
| Bupivacaine liposome injectable suspension | 1,206 | 291 | |||||
| Total EXPAREL / bupivacaine liposome injectable suspension net product sales | 102,475 | 90,906 | |||||
| iovera° | 2,270 | — | |||||
| Total net product sales | 104,745 | 90,906 | |||||
| Royalty revenue | 939 | 407 | |||||
| Total revenues | $ | 105,684 | $ | 91,313 | |||
| Operating expenses: | |||||||
| Cost of goods sold | 29,732 | 27,303 | |||||
| Research and development | 15,819 | 14,384 | |||||
| Selling, general and administrative | 44,780 | 47,305 | |||||
| Amortization of acquired intangible assets | 1,967 | — | |||||
| Acquisition-related (gains) charges and product discontinuation, net | (3,708 | ) | 1,242 | ||||
| Total operating expenses | 88,590 | 90,234 | |||||
| Income from operations | 17,094 | 1,079 | |||||
| Other (expense) income: | |||||||
| Interest income | 1,589 | 2,156 | |||||
| Interest expense | (6,022 | ) | (5,814 | ) | |||
| Other, net | (4,104 | ) | 61 | ||||
| Total other expense, net | (8,537 | ) | (3,597 | ) | |||
| Income (loss) before income taxes | 8,557 | (2,518 | ) | ||||
| Income tax expense | (398 | ) | (253 | ) | |||
| Net income (loss) | $ | 8,159 | $ | (2,771 | ) | ||
| Net income (loss) per share: | |||||||
| Basic and diluted net income (loss) per common share | $ | 0.19 | $ | (0.07 | ) | ||
| Weighted average common shares outstanding: | |||||||
| Basic | 42,032 | 41,240 | |||||
| Diluted | 42,785 | 41,240 | |||||
Reconciliation of GAAP to Non-GAAP Financial Information
(in thousands, except per share amounts)
(unaudited)
| Three Months Ended | |||||||
| 2020 | 2019 | ||||||
| GAAP net income (loss) | $ | 8,159 | $ | (2,771 | ) | ||
| Non-GAAP adjustments: | |||||||
| Acquisition-related (gains) charges and product discontinuation, net | (3,708 | ) | 1,242 | ||||
| Stock-based compensation | 8,847 | 7,434 | |||||
| Amortization of debt discount | 3,594 | 3,345 | |||||
| Amortization of acquired intangible assets | 1,967 | — | |||||
| Loss on investment | 3,971 | — | |||||
| Total Non-GAAP adjustments | 14,671 | 12,021 | |||||
| Non-GAAP net income | $ | 22,830 | $ | 9,250 | |||
| GAAP basic and diluted net income (loss) per common share | $ | 0.19 | $ | (0.07 | ) | ||
| Non-GAAP basic net income per common share | $ | 0.54 | $ | 0.22 | |||
| Non-GAAP diluted net income per common share | $ | 0.53 | $ | 0.22 | |||
| Weighted average common shares outstanding - basic | 42,032 | 41,240 | |||||
| Weighted average common shares outstanding - diluted | 42,785 | 42,117 | |||||
| Cost of goods sold reconciliation: | |||||||
| GAAP cost of goods sold | $ | 29,732 | $ | 27,303 | |||
| Stock-based compensation | (1,219 | ) | (1,091 | ) | |||
| Non-GAAP cost of goods sold | $ | 28,513 | $ | 26,212 | |||
| Research and development reconciliation: | |||||||
| GAAP research and development | $ | 15,819 | $ | 14,384 | |||
| Stock-based compensation | (1,186 | ) | (1,218 | ) | |||
| Non-GAAP research and development | $ | 14,633 | $ | 13,166 | |||
| Selling, general and administrative reconciliation: | |||||||
| GAAP selling, general and administrative | $ | 44,780 | $ | 47,305 | |||
| Stock-based compensation | (6,442 | ) | (5,125 | ) | |||
| Non-GAAP selling, general and administrative | $ | 38,338 | $ | 42,180 | |||
Investor Contact:Susan Mesco , (973) 451-4030 susan.mesco@pacira.com Media Contact:Coyne Public Relations Alyssa Schneider , (973) 588-2270 aschneider@coynepr.com
Source: Pacira BioSciences